About
The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. eureKARE has a two-step investment approach to deliver long-term value creation. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry. eureKARE participates in DNA Script’s $200 Million Series C Financing Fundraise will accelerate commercial launch of revolutionary enzymatic DNA printing technology Luxembourg and Paris, France – January 4, 2022 (TBD): eureKARE ("the Company"), a pioneering company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, is pleased to announce that it has participated in DNA Script’s $200 million Series C financing which today closed with completion of the second tranche.
